IMAB (i-mabbiopharma.com) Long-Term Debt

Graphic logo of I-Mab Biopharma Co., Ltd. (IMAB)

I-Mab (IMAB) develops cutting-edge antibodies to combat tumors, generating steady revenue through licensing agreements with pharmaceutical behemoths. The updated management has successfully segregated international assets, focusing on U.S. clinical developments. The business relies on stable, non-seasonal demand, and the current metric stands at 0.00. The company's price evolution is illustrated in the chart below.

IMAB I-Mab Biopharma Co., Ltd.: Company Long-Term Debts in the range 07/04/2022 - 10/30/2025

Analytical breakdowns for I-Mab

- price and consensus price forecast:
Share Price I-Mab Biopharma Co., Ltd.|IMAB - Analyst Consensus Forecast
- market capitalization data:
Market Value I-Mab|IMAB - Total Company Value
- book capitalization data:
Accounting Value of a Share I-Mab|IMAB - Book Capitalization|Market Capitalization to Book Value Ratio i-mabbiopharma.com|IMAB - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity I-Mab|IMAB - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital I-Mab Biopharma Co., Ltd.|IMAB - Company Debts|Debts to Book Value I-Mab|IMAB - Company Long-Term Debt|Company Short-Term Indebtedness I-Mab
Fundamental valuation:I-Mab (IMAB)
Mass-produced product of I-Mab Inc.

Developing monoclonal antibodies for oncology requires colossal expenditures on multi-year clinical trials. When analyzing the long-term debt of I-Mab (IMAB), an investor tracks the dynamics of strategic obligations with maturities exceeding one year. This metric captures the volume of external financing, making it possible to distinguish investments in a technological leap from signs of an impending liquidity shortage. The stability of this indicator confirms the resilience of the foundation for future profits.

Competitor analysis

Company Long-Term Indebtedness incyte.com INCY|HCM (HUTCHMED) - Company Long-Term Debts|NUVB: Long-Term Debt|Company Long-Term Debt Day One Bio DAWN|Monopar Corp (MNPR) - Company Long-Term Loans and Borrowings|INBX (Inhibrx Biosciences) - Company Long-Term Debts|Company Long-Term Debts FENC|Company Long-Term Debt Heron Therapeutics (HRTX)|Company Long-Term Debt Nuvectis Pharma Inc. NVCT|Company Long-Term Liabilities coherus.com|Corbus Pharmaceuticals, Inc. - Company Long-Term Loans and Borrowings|CRDF (Cardiff Oncology Corp) - Company Long-Term Debt|BYSI: Long-Term Debt|Company Long-Term Debt bioatla.com|Lixte Biotechnology Holdings Inc. (LIXT) - Company Long-Term Indebtedness|Company Long-Term Debts CTXR|Company Long-Term Liabilities CLRB|BioLineRx Ltd. - Company Long-Term Debt|Long-Term Debt CANF (canfite.com)|Company Long-Term Debt Aprea Therapeutics, Inc. APRE|Kazia Therapeutics Ltd - Company Long-Term Debt|SLXN (Silexion) - Company Long-Term Debt|NCNA - Long-Term Debt|Company Long-Term Debts CMRX (Chimerix, Inc.)|Long-Term Indebtedness cyclacel.com|Company Long-Term Liabilities GTHX (G1 Therapeutics Inc.)|Long-Term Debt Kronos Bio Inc (KRON)|Kintara (KTRA) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings Oncternal Corp ONCT|Company Long-Term Liabilities Portage Biotech Inc. (PRTG)